← Oncology Approval Tracker

FDA DECISION ·

Elrexfio

elranatamab-bcmm · Pfizer

FDA approvalNew dosing regimenMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 76 mg every four weeks from week 49 for patients who maintained a response through at least 24 weeks of every-two-weeks treatment under the existing relapsed or refractory multiple myeloma indication.

LAMPGEN ANALYSIS

Why it matters

The extension can reduce clinic visits for patients with an established response while the original accelerated disease indication remains distinct.

What research teams should watch

Document response and time on prior dosing before spacing visits; maintain infection surveillance and clear instructions for dosing delays.

PRIMARY RECORDS

Sources